NCT03713580 Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03710772 Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03709758 Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03708003 Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL Status TERMINATED Phase PHASE2
NCT03701321 Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma Status WITHDRAWN Phase PHASE1/PHASE2
NCT03701282 Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03661307 Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Status RECRUITING Phase PHASE1/PHASE2
NCT03634228 Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia Status TERMINATED Phase PHASE1/PHASE2
NCT03629171 Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Status RECRUITING Phase PHASE2
NCT03625505 A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia Status COMPLETED Phase PHASE1
NCT03613532 Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03609593 Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Status COMPLETED Phase PHASE2
NCT03586609 Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia Status RECRUITING Phase PHASE2
NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy Status TERMINATED Phase PHASE2
NCT03583424 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT03580928 Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03576547 Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Status TERMINATED Phase PHASE1/PHASE2
NCT03573024 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2